About Heron Therapeutics
Heron Therapeutics is a publicly listed company based in Redwood City (United States) founded in 1983. It operates as a reformulated injectables for chemotherapy side effects and pain are developed. It operates on a Direct-to-Consumer (D2C) model. The company has 122 employees. Heron Therapeutics offers products and services including SUSTOL, CINVANTI, ZYNRELEF, and APONVIE. Its focus areas include Biotechnology and Therapeutics. Its legal entity is Heron Therapeutics, Inc. Its competitors include Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma and 2 more; 7 of its 7 listed competitors have raised funding.
Company details
Heron Therapeutics is dedicated to advancing therapeutic standards for patients through innovative science and technologies. The company is engaged in developing and commercializing a portfolio of best-in-class therapies aimed at addressing unmet medical needs in acute care and oncology sectors. Solutions such as SUSTOL, CINVANTI, ZYNRELEF, and APONVIE are provided to prevent issues like chemotherapy-induced nausea, vomiting, and postoperative pain. The focus is placed on improving patient outcomes by rethinking treatment approaches and reducing reliance on opioids in surgical settings.
- Headquarters Redwood City, United States
- Employees 122
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phone•••• ••••
- Website herontx.com
- Social LinkedIn
- Legal Name Heron Therapeutics, Inc.
- Annual Revenue$154.9 M (USD)7.36as on Dec 31, 2025
- Net Profit-$20.2 M (USD)-48.71as on Dec 31, 2025
- EBITDA-$224 K (USD)97.52as on Dec 31, 2025
- Latest Funding Round$30M (USD), Post-IPO
Jul 2023
- InvestorsHercules Capital
& 6 more
- Employee Count122
Products & Services of Heron Therapeutics
Heron Therapeutics offers a comprehensive portfolio of products and services, including SUSTOL, CINVANTI, ZYNRELEF, and APONVIE.
Used for preventing chemotherapy-induced nausea and vomiting.
Administered to prevent nausea and vomiting from chemotherapy.
Designed for managing postoperative pain in patients.
Utilized for preventing postoperative nausea and vomiting.
Funding Insights of Heron Therapeutics
- Total Rounds 10
- Last Round Post-IPO — $30M
- First Round $8.14M
(Nov 2009)
- Investors Count 7
All 10 funding rounds of Heron Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2023 | $30M | Post-IPO | – | – | |
| Aug 2022 | $76.5M | Post-IPO | – | – | |
| May 2021 | $150M | Post-IPO | – | – | – |
| Mar 2018 | $156M | Post-IPO | – | – | – |
| Jul 2012 | $53.55M | Post-IPO | – | – | – |
| Jul 2011 | $24M | Unspecified | – | – | – |
| Jul 2011 | $24M | Post-IPO | – | – | – |
| May 2011 | $1.5M | Debt – Conventional | – | – | – |
| Nov 2009 | $8.14M | Unspecified | – | – | – |
| Nov 2009 | $8.14M | Post-IPO | – | – | – |
7 investors in total: 7 institutional.
Investors in Heron Therapeutics
Heron Therapeutics has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Hercules Capital, Rubric Capital and Velan Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | velancapital.com | - | |
Clearline Capital, LLC is engaged in emerging market debt solutions. | 2016 | clearlinecapital.com | - | |
Venture debt financing is provided to companies in multiple sectors. | 2003 | htgc.com | Palo Alto, United States | |
Deep Track Capital is engaged in biotechnology investment activities. | – | deeptrackcapital.com | Greenwich, United States | |
Private equity firm focused on company buyouts | – | gppfunds.com | Greenwich, United States | |
Investment opportunities in healthcare are managed by Broadfin Capital. | 2005 | broadfin.com | Melville, United States | |
Investment management services are offered by Rubric Capital. | – | rubriccapital.com | New York, United States |
Investor details for Heron Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Heron Therapeutics
87 people are tracked at Heron Therapeutics (39 in leadership, 5 in board & advisors, 43 in team); the tracked headcount is 122.
| Name | Role | Group |
|---|---|---|
John Arthur | Vice President Manufacturing And Supply | Leadership |
Adriane Morris | Director, Human Resources | Leadership |
Ira Duarte | EVP & CFO | Leadership |
Pierre Thoumsin | National Account Director | Leadership |
Robert Sullivan | Sr. Vice President, Commercial Operations | Leadership |
Craig Collard | Chief Executive Officer | Leadership |
Ryan Craig | Vice President Marketing | Leadership |
David Barozzino | Vice President Of Sales, Acute Care | Leadership |
Andy Erickson | Sr. Director, Payer And Reimbursement | Leadership |
Wayne Kong | Director Of Supply Chain Management And Logistics | Leadership |
Colleen Gerow | Director, Finance Operations | Leadership |
Risha Gatmaitan | Associate Director Quality Control - Stability | Leadership |
Bobby Pope | Vice President, National Accounts And Strategic Alliances | Leadership |
Terra Spignardo | National Sales Director- Strategic Customer Group | Leadership |
Garrett Schwing | National Sales Director, Acute Care | Leadership |
Nancy Knochel | Human Resources Director | Leadership |
Jason Chu | Executive Director Finance | Leadership |
Mike Schultz | Director, National Accounts | Leadership |
Gail Shirley | Associate Director Contract Operations | Leadership |
Isabel Garcia | Director, Regulatory Operations | Leadership |
67 more people are available in the full profile.
Complete people profiles for Heron Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Heron Therapeutics
Heron Therapeutics is a publicly listed company on the NASDAQ with ticker symbol HRTX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date26 Aug 1987
- Listed onNASDAQ: HRTX
- Listed entityHeron Therapeutics, Inc.
- Exchange sectorHealth technology
- ISINUS4277461020
- Share price$0.39 (-6.02% on the day) · 2026-10-13
- Market capitalisation$74.2M
- EPS (diluted, trailing year)$-0.19
- Volume (last session)1,861,114
Financials of Heron Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $154.9M | -$20.2M | -$224,000 |
| 2024 | $144.3M | -$13.6M | -$9.0M |
| 2023 | $127.0M | -$110.6M | -$107.7M |
| 2022 | $107.7M | -$182.0M | -$166.4M |
| 2021 | $86.3M | -$220.7M | -$213.2M |
Detailed financial statements for Heron Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Heron Therapeutics
4 dated milestones of Heron Therapeutics across 40 years, from founding to its latest funding, stage changes and deals.
- Founded Heron Therapeutics is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $8.1M.
- Funding Latest funding round, Post-IPO, of $30.0M.
Competitors of Heron Therapeutics
Heron Therapeutics has 7 listed competitors in our database, 7 of them funded. They include Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| miragen.com | 2007 | Boulder, United States | $111.29M | 92 | MicroRNA-based therapeutics are developed for treating multiple diseases. | |
| mereobiopharma.com | 2015 | London, United Kingdom | $119M | 56 | Therapeutics for cancer and rare diseases are developed. | |
| nimbustx.com | 2009 | Cambridge, United States | $685M | 81 | Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. | |
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. |
Detailed competitors of Heron Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Heron Therapeutics
The website of Heron Therapeutics (herontx.com) receives about 8.4K visits a month and ranks #2,806,627 among all websites worldwide, #3,768 in Biotechnology and Pharmaceuticals.
- Monthly visits8.4K
▲ 25% vs previous month
- Unique visitors3K
per month
- Global rank#2,806,627
among all websites
- Category rank#3,768
Health · Biotechnology and Pharmaceuticals
- Bounce rate48%
- Pages per visit2.1
- Average visit27 sec
- DevicesDesktop 56% · Mobile 44%
Top companies in Pain Management
10 companies that operate in the same segment as Heron Therapeutics (Pain Management), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
Developer of therapeutics for pain relief and inflammatory diseases | 2004 | New York, New York, United States | USD 51 M | USD 4.33 M | 79 | |
GPCR ligand-based therapeutics for cardiovascular diseases and pain are developed. | 2007 | Philadelphia, Pennsylvania, United States | USD 203 M | USD 3.13 M | 35 | |
Therapeutics for migraine treatment are developed using nasal delivery. | 2016 | San Francisco, California, United States | USD 74.13 M | – | 24 | |
Pain treatment products are developed through reformulation technologies. | 2007 | Herzliya, Central District, Israel | USD 12 M | USD 17 K | 6 | |
Drug delivery systems for CNS disorders and pain are developed. | 2006 | Emeryville, California, United States | USD 149.06 M | – | – | |
Developer of neuromodulation platform measuring biomarkers for chronic neurological condition treatment | 2010 | Bloomington, Indiana, United States | USD 530 M | USD 91.65 M | – | |
Therapies for pain and addiction treatment are developed. | 1977 | Saint-cloud, France | USD 248.09 M | USD 167.87 M | – | |
Novel drug products for chronic pain treatment are developed. | 2007 | Blue Bell, Pennsylvania, United States | USD 12.96 M | – | 17 | |
Abuse-deterrent extended-release therapeutics for chronic pain are developed. | 2002 | Canton, Ohio, United States | USD 103 M | USD 780.57 M | 357 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Heron Therapeutics
Complete news archive for Heron Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Heron Therapeutics
Heron Therapeutics was founded in 1983 and raised its 1st funding round 26 years after it was founded.
Heron Therapeutics is headquartered in Redwood City, United States. It is registered at Redwood City, California, United States.
Heron Therapeutics has 122 employees.
Annual revenue of Heron Therapeutics is $154.9M as on Dec 31, 2025.
Heron Therapeutics is dedicated to advancing therapeutic standards for patients through innovative science and technologies. The company is engaged in developing and commercializing a portfolio of best-in-class therapies aimed at addressing unmet medical needs in acute care and oncology sectors. Solutions such as SUSTOL, CINVANTI, ZYNRELEF, and APONVIE are provided to prevent issues like chemotherapy-induced nausea, vomiting, and postoperative pain. The focus is placed on improving patient outcomes by rethinking treatment approaches and reducing reliance on opioids in surgical settings.
Heron Therapeutics's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Heron Therapeutics offers SUSTOL, CINVANTI, ZYNRELEF, and APONVIE.
Yes, Heron Therapeutics is publicly traded on NASDAQ under the ticker symbol HRTX.
Heron Therapeutics has 7 investors. Key investors include Hercules Capital, Rubric Capital, Velan Capital, Clearline Capital, and Deep Track Capital.
Heron Therapeutics operates through Heron Therapeutics, Inc..